89
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Long non-coding RNA MALAT1 regulates hyperglycaemia induced inflammatory process in the endothelial cells

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To examine whether the long non-coding RNA (lncRNA) metastasis associated lung adenocarcinoma transcript 1 (MALAT1) is altered in the endothelial cells in response to glucose and the significance of such alteration. We incubated human umbilical vein endothelial cells with media containing various glucose levels. We found an increase in MALAT1 expression peaking after 12 hrs of incubation in high glucose. This increase was associated with parallel increase in serum amyloid antigen 3 (SAA3), an inflammatory ligand and target of MALAT1 and was further accompanied by increase in mRNAs and proteins of inflammatory mediators, tumour necrosis factor alpha (TNF-α) and interleukin 6 (IL-6). Renal tissue from the diabetic animals showed similar changes. Such cellular alterations were prevented following MALAT1 specific siRNA transfection. Results of this study indicate that LncRNA MALAT1 regulates glucose-induced up-regulation of inflammatory mediators IL-6 and TNF-α through activation of SAA3. Identification of such novel mechanism may lead to the development of RNA-based therapeutics targeting MALAT1 for diabetes-induced micro and macro vascular complications.

          Related collections

          Most cited references10

          • Record: found
          • Abstract: found
          • Article: not found

          Contributions of Inflammatory Processes to the Development of the Early Stages of Diabetic Retinopathy

          Diabetes causes metabolic and physiologic abnormalities in the retina, and these changes suggest a role for inflammation in the development of diabetic retinopathy. These changes include upregulation of iNOS, COX-2, ICAM-1, caspase 1, VEGF, and NF- κ B, increased production of nitric oxide, prostaglandin E2, IL-1 β , and cytokines, as well as increased permeability and leukostasis. Using selective pharmacologic inhibitors or genetically modified animals, an increasing number of therapeutic approaches have been identified that significantly inhibit development of at least the early stages of diabetic retinopathy, especially occlusion and degeneration of retinal capillaries. A common feature of a number of these therapies is that they inhibit production of inflammatory mediators. The concept that localized inflammatory processes play a role in the development of diabetic retinopathy is relatively new, but evidence that supports the hypothesis is accumulating rapidly. This new hypothesis offers new insight into the pathogenesis of diabetic retinopathy, and offers novel targets to inhibit the ocular disease.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Molecular insights and therapeutic targets for diabetic endothelial dysfunction.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Aberrant expression of long noncoding RNAs in early diabetic retinopathy.

              Long noncoding RNAs (lncRNAs) are broadly classified as transcripts longer than 200 nucleotides. lncRNA-mediated biology has been implicated in a variety of cellular processes and human diseases. Diabetic retinopathy (DR) is one of the leading causes of blindness. However, little is known about the role of lncRNAs in DR The goal of this study aimed to identify lncRNAs involved in early DR and characterize their roles in DR pathogenesis.
                Bookmark

                Author and article information

                Journal
                J Cell Mol Med
                J. Cell. Mol. Med
                jcmm
                Journal of Cellular and Molecular Medicine
                BlackWell Publishing Ltd (Oxford, UK )
                1582-1838
                1582-4934
                June 2015
                19 March 2015
                : 19
                : 6
                : 1418-1425
                Affiliations
                Department of Pathology, Schulich School of Medicine and Dentistry, Western University London, Ontario, Canada
                Author notes
                * Correspondence to: Dr. Subrata CHAKRABARTI, Department of Pathology, Western University, London, Ontario, Canada., Tel.: (519) 685-8500, ext. 36350, Fax: 519-663-2930, E-mail: subrata.chakrabarti@ 123456lhsc.on.ca
                Article
                10.1111/jcmm.12576
                4459855
                25787249
                26ade35f-0470-4982-9f62-7f1a457a8a27
                © 2015 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.

                This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 23 October 2014
                : 05 February 2015
                Categories
                Original Articles

                Molecular medicine
                endothelial cells,malat1,il6,tnfα,kidney,diabetes,glucose
                Molecular medicine
                endothelial cells, malat1, il6, tnfα, kidney, diabetes, glucose

                Comments

                Comment on this article